Literature DB >> 22631040

The definition and epidemiology of non-transfusion-dependent thalassemia.

David J Weatherall1.   

Abstract

Inherited hemoglobin-related disorders, which include the structural variants (hemoglobin S, C, and E) and the alpha (α)- and beta (β)-thalassemias, affect more than 300,000 children annually, particularly in malaria-endemic regions stretching from sub-Saharan Africa and the Mediterranean to Southeast Asia. Screening for carriers of these traits is important to provide prenatal genetic counseling and to accurately estimate the true prevalence and public health burden of these disorders. The clinical course of thalassemias, which affect nearly 70,000 children annually, is highly variable depending on the mixture of inherited alleles. The primary forms of non-transfusion-dependent thalassemia include β-thalassemia intermedia, hemoglobin E β-thalassemia, and hemoglobin H disease. Early clinical recognition of these disorders is essential to prevent affected children from being mistakenly placed on life-long transfusion therapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22631040     DOI: 10.1016/S0268-960X(12)70003-6

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  45 in total

1.  Iron overload correlates with serum liver fibrotic markers and liver dysfunction: Potential new methods to predict iron overload-related liver fibrosis in thalassemia patients.

Authors:  Man Wang; Rongrong Liu; Yuzhen Liang; Gaohui Yang; Yumei Huang; Chunlan Yu; Kaiqi Sun; Yongrong Lai; Yang Xia
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

2.  Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors.

Authors:  Adisak Tantiworawit; Pimlak Charoenkwan; Sasinee Hantrakool; Worawut Choeyprasert; Chate Sivasomboon; Torpong Sanguansermsri
Journal:  Int J Hematol       Date:  2016-04-06       Impact factor: 2.490

3.  Striking the target in iron overload disorders.

Authors:  Karin E Finberg
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

4.  α:Non-α and Gγ:Aγ globin chain ratios in thalassemia intermedia patients treated with hydroxyurea.

Authors:  Abbas Najjari; Mohsen Asouri; Ladan Hosseini Gouhari; Haleh Akhavan Niaki; Amir Sasan Mozaffari Nejad; Seyyedeh Masoumeh Eslami; Hassan Abolghasemi; Ramin Ataee; Abdol Ali Ebrahimi; Masoumeh Rezaei Moshaei; Ali Asghar Ahmadi
Journal:  Asian Pac J Trop Biomed       Date:  2014-05

5.  Cortical bone invasion in non-transfusion-dependent thalassemia: tumefactive extramedullary hematopoiesis reviewed.

Authors:  Karim Z Masrouha; Joelle Wazen; Anthony Haddad; Fadi Saadeh; Ali Taher; Nabil J Khoury
Journal:  Radiol Med       Date:  2016-04-23       Impact factor: 3.469

6.  A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy.

Authors:  Sherif M Badawy; Usman Beg; Robert I Liem; Sonali Chaudhury; Alexis A Thompson
Journal:  Blood Adv       Date:  2021-01-26

Review 7.  Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.

Authors:  Wai Cheng Foong; Jacqueline J Ho; C Khai Loh; Vip Viprakasit
Journal:  Cochrane Database Syst Rev       Date:  2016-10-18

8.  Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.

Authors:  Shuling Guo; Carla Casu; Sara Gardenghi; Sheri Booten; Mariam Aghajan; Raechel Peralta; Andy Watt; Sue Freier; Brett P Monia; Stefano Rivella
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

Review 9.  Gene therapy for hemoglobinopathies: progress and challenges.

Authors:  Alisa Dong; Stefano Rivella; Laura Breda
Journal:  Transl Res       Date:  2013-01-19       Impact factor: 7.012

Review 10.  β-Thalassemia intermedia: a comprehensive overview and novel approaches.

Authors:  Chingiz Asadov; Zohra Alimirzoeva; Tahira Mammadova; Gunay Aliyeva; Shahla Gafarova; Jeyhun Mammadov
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.